eligibility_summary
Inclusion: Solid tumors (UC, TNBC, NSCLC, esophageal, pancreatic, ovarian, cervical SCC, HNSCC, prostate). Prior therapy: A1/C all standard or none available, A2/B1/B2 ≥1 line. Enfortumab vedotin (EV): A1/A2/C allowed, B1 EV‑naive, B2 EV‑exposed. Disease measurable (A1 may be non‑measurable). ECOG 0–1, tissue available. Exclusion: uncontrolled CNS mets, hypercalcemia/diabetes, corneal dz/transplant, unresolved tox, CV dz, VTE/bleeding, QTcF≥470, ILD/pneumonitis, ≥G3 EV skin tox, preg/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: LY4052031, an intravenous antibody–drug conjugate (ADC). Mechanism: a monoclonal antibody binds Nectin‑4 on tumor cells, is internalized, and releases a linked cytotoxic payload intracellularly to kill the cancer cell. Type: targeted cytotoxic immunotherapy (ADC). Targets: Nectin‑4–expressing epithelial tumor cells, pathway centered on Nectin‑4 (a cell-adhesion molecule in the nectin family) frequently overexpressed in urothelial carcinoma and select solid tumors (e.g., TNBC, NSCLC, esophageal, pancreatic, ovarian, cervical, HNSCC, prostate).